Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Microbot Medical Inc. (Nasdaq:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, closed the previously disclosed asset purchase agreement with BOCO Silicon Valley, Inc., a wholly-owned subsidiary of Bright Oceans Corporation, for proceeds to the Company of $3,460,000. These proceeds include $255,000 which was previously paid to the Company’s predecessor, StemCells Inc., and $400,000 which will be held in escrow for 12 months to assure performance of contractual representations and warranties, but exclude consulting fees paid directly from escrow at closing to former StemCells employees involved in the asset transfer.
The transferred assets included stem and progenitor cell lines that belonged to the predecessor company, StemCells, which completed a merger with the Company on November 28, 2016. The resources from the asset sale will be used to further develop the Company’s transformational micro-robotic technologies that are designed to treat and diagnose various medical conditions. The Company’s initial products are expected to address the unmet medical needs for Cerebrospinal Fluid (CSF) and Gastrointestinal (GI), and are expected to be submitted the FDA in the near future.
“The proceeds enhance our balance sheet in a non-dilutive manner and allow us to add key management hires as well as continue focusing on the development of our innovative micro-robotic technologies,” commented Harel Gadot, Chairman and Chief Executive Officer. “The products borne from these technologies will allow us to enhance the quality of life and address unmet medical needs impacting millions of patients globally.”
Oh, very fast! I have now the new shares in my account!
Now we need numbers, what Microbot may worth, with it pipeline and sells!
Ouch! We need news and numbers from Microbot!
Tha other company from the CEO (MZOR) is going up 50% in one month, after it goes on NASDAQ...
I´m can´t sell the next 3? days?
Hope this is worth 300 MIO in minimum.
The little Roboter is very nice and if it running ...
http://www.microbotmedical.com/technology/virob/
So lets look what will happen with this new Ticker!
The big Question is, how high is the MCAP of the New Stock?
Microbot Medical Closes Merger Transaction; Initiates Trading on NASDAQ as ‘MBOT’
Navidea will receive $80 million at closing, plus the opportunity to earn up to $230 million of contingent consideration based on certain milestones through 2026, with $20.1 million of that amount guaranteed over the next 3 years.
As part of the transaction, Cardinal Health will license a portion of the acquired intellectual property back to Navidea to allow Navidea to develop and sell new immunodiagnostic and immunotherapeutic products for specific purposes in North America, and to continue to produce and sell Lymphoseek, mostly under a different brand, outside of North America.
waiting for SHORTSQUEEZE!
unbeleavable, that they bringing the pps down to 0.93$!
With that cash, NAVB can pay all her liabilities!
After the sell-on-news-steam is over and the shorters seeing that is not going more down, this will fly!
Mast Therapeutics (NYSE:MSTX) last announced its quarterly earnings results on Tuesday, November 8th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01.
support 2 times testet, now i think we close green again!
Green close so far! It´s a good sign, nearly all my other shares on the watchlist are red today.
Hope Clay is not a bad omen, and hope he is right with his "higher base building"!
Now we must break the 0.10-0.105 area and than it will fly EOD!
enough is enough. now go up! Mcap is at this levels a little bit over the cash! selling at this level is a joke!
I think it will go up. now is selling with gain from the upper pennyrange. selling will dry up, than it goes higher!
if it break the 0.105+$ than it goes much more
UP! Next stop 0.135!
Sometimes, the smallest stocks can get the biggest attention. That's what's happening in shares of microcap biopharmaceutical firm Mast Therapeutics (MSTX) , a tiny stock that's up 16% this afternoon on volume high enough to make it one of the most actively traded issues on the NYSE. Mast has been in freefall in the last few months, but management's report today that the company is evaluating strategic alternatives, including the possibility of a reverse merger with a privately held company, is re-energizing investors.
https://www.thestreet.com/story/13901244/4/how-to-trade-these-most-active-stocks-lifelock-tyson-foods-and-more.html
Preliminary Indications of Interest in Reverse Merger Transactions. The Company has received several written indications of interest from privately-held companies, including companies with synergistic clinical-stage drug candidates, and is actively evaluating these opportunities.
Other Strategic Opportunities. Concurrently, the Company will continue to explore ways to strategically monetize its vepoloxamer assets, including through licensing transactions.
Continued Clinical Development of AIR001. In parallel with exploring strategic opportunities, the Company will continue to support ongoing and planned investigator-sponsored clinical studies of its lead asset, AIR001, for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).
Potencial Mergernews, and the stock is on +17% after the 40% from the start!
So, lets look what will happen today! 7 days to Merger...
to complete its merger with Microbot on or before November 28, 2016.
Clay, the dark omen befor Shortattacks! Cover guys and let it go up to 2.++$
Net Revenues were $41.5 million, an increase of 13% over the second quarter and a decrease of 15% compared to the same period in the prior year.
Prescription volumes grew sequentially and year-over-year for all three core brands, Treximet, Zohydro ER with BeadTek, and Silenor.
Gross Margin was 73.9%, an improvement of 710 basis points over the second quarter 2016 and a decrease of 130 basis points over the same prior year period.
Net loss was $26.4 million for the three months ended September 30, 2016, as compared to $31.1 million for the three months ended June 30, 2016 and $10.7 million for the prior year period.
Adjusted EBITDA improved to $8.4 million as compared with ($1.4 million) in the second quarter 2016 and decreased $0.3 million from the prior year period.
Business Update:
Solid increases in prescription volumes in the third quarter due to continued momentum and focused efforts on highest volume prescribers
Treximet TRx up 4% sequentially and 2% year-over-year
Zohydro ER TRx up 5% sequentially and 16% year-over-year
Silenor TRx up 0.3% sequentially and 7% year-over-year
Began distributing Treximet pediatric dose for patients age 12 and older
Provides important therapeutic option to pediatric migraine sufferers
Issued two new Orange Book patents for Zohydro ER® with BeadTekTM strengthening intellectual property protection through 2033
Company has 6 Orange Book listed patents valid through 2033 broadly directed to methods of dosing patients with mild or moderate hepatic impairment with hydrocodone
Initiated new clinical development efforts to strengthen abuse-deterrent characteristics of Zohydro ER
Focused on the development of a next-generation version of Zohydro ER
Implemented a 1-for-10 reverse stock split effective on October 14th in order to raise the per share trading price of the Company’s common stock and comply with NASDAQ continued listing requirements
Announced the appointment of Graham G. Miao, Ph.D. and Dennis H. Langer, M.D., J.D. to the Company’s Board of Directors on November 7, 2016, effective immediately. Accordingly, Pernix regained compliance with NASDAQ Listing Rule 5605(c)(2)(A), which requires Pernix to have at least three independent directors on its Audit Committee for continued listing on The NASDAQ Global Market
MMs and her Games! Who is setting the bid to 3.00 or 3.40?
And than a 145 Shares-Sell in Premarket?
Looks like the Shorters are wishing a lower price to cover, and some others wishing a lower entry!
On Friday the Shorters are strong, but they must cover befor the pps going up!
On last 10Q it was on 7.xx! This is better!
For the three months ended September 30, 2016, net revenues were $41.5 million compared to $36.7 million for the three months ended June 30, 2016, an increase of 13%.
uihui all the stoplosses now triggert, befor it goes up!?
Third Quarter 2016 Financial and Product Highlights:
Net Revenues were $41.5 million, an increase of 13% over the second quarter and a decrease of 15% compared to the same period in the prior year.
Prescription volumes grew sequentially and year-over-year for all three core brands, Treximet, Zohydro ER with BeadTek, and Silenor.
Gross Margin was 73.9%, an improvement of 710 basis points over the second quarter 2016 and a decrease of 130 basis points over the same prior year period.
Net loss was $26.4 million for the three months ended September 30, 2016, as compared to $31.1 million for the three months ended June 30, 2016 and $10.7 million for the prior year period.
Adjusted EBITDA improved to $8.4 million as compared with ($1.4 million) in the second quarter 2016 and decreased $0.3 million from the prior year period.
Looks positiv!
So, now let us see the numbers, sharenumber and the cash!
EARNINGS today AMC!
In reaction to the results of the EOP2 meeting, which the analyst praises as “better than we could have hoped for,” he reiterates a Buy rating on shares of AUPH with a $10 price target, which represents a 295% increase from current levels.
http://www.smarteranalyst.com/2016/11/07/h-c-wainwright-believes-aurinia-pharmaceuticals-inc-auph-wins-big-results-end-phase-2-meeting-fda/
Last time it goes from 4.10 to 4.68 in under 20 minutes! So i think eod 4.++ is no problem!
Low volume today! Only 100k at the moment!
Looks like the base is 3.62$. Now is the question, who covers first and makes the most money on bringing down the stock!
I think we going back to 4.++ today!
With a little buyingpressure we can have the next shortsqeez befor weekend!
... this isn't some fly by night OTC. Haha
Look at the Numbers! Shorters and Daytraders making it to a OTC Stock!
On command they shorting the hell out of the stock!
First the 10% flippers selling, if it goes up a little, than the shorters bring it down! And that all without any News, changes in the numbers or something else!
Normal People, that putting her Money in the Stock after looking at the Sales, Pipeline etc. loosing her money on fear or Stoplosses etc.
Yesterday are the shortshares on a new high!
http://shortanalytics.com/getshortchart.php?tsymbol=ptx
Hui, one houre and the shorts bring it to 3.65$, like clay had predicted!
The 10 days are gone. We need 1-2 good PR´s to let the shorters and 10% daytraders behind us!